NY-BLACKSTONE
22.2.2021 08:32:07 CET | Business Wire | Press release
Blackstone (NYSE:BX) today announced the appointment of former Centrica CEO, Iain Conn, as a Senior Advisor for energy and sustainability investing. Conn will bring his deep knowledge of the energy sector, climate and sustainability to advise across the firm’s infrastructure and energy businesses.
Blackstone has a long history of acquiring, building and financing renewable and energy efficiency projects. In the past twelve months alone, Blackstone has made meaningful investments including Aypa (formerly known as NRstor) , a battery energy storage pioneer, and Therma Holdings LLC , a leading provider of mechanical, electrical and energy efficiency services, among others; Iain’s appointment will help to further these efforts.
Commenting on the appointment, Sean Klimczak, Global Head of Blackstone Infrastructure Partners said: “Iain’s knowledge of the energy sector will be invaluable as we invest in infrastructure that supports the energy transition toward a more sustainable, decarbonized future. We look forward to benefiting from Iain’s insights, which will better the firm and improve our portfolio for our investors.”
David Foley, Global Head of Blackstone Energy Partners said: “I have known Iain for two decades and I look forward to working with him on private equity investment opportunities, particularly in the energy efficiency and retail electric sectors.”
Iain Conn, former Centrica CEO, said: “I am honored to advise Blackstone. They are already investing in the energy transition and demonstrating leadership in tackling climate change by committing to reduce carbon emissions by 15% across all new investments where the firm controls energy usage. I’m excited to see what the future holds for the firm and the Blackstone portfolio.”
Conn has over 34 years of executive experience in the energy sector, including 29 years with BP plc, latterly as CEO Downstream from 2007-2014. Most recently, from 2015-2020 he was Group Chief Executive of Centrica plc, a Fortune 500 and FTSE 100 energy, services and lower-carbon solutions company. Centrica, which included British Gas, had revenues of £30bn and over 25,000 employees. Conn drove the strategy to reposition the company back to being customer-centric and oriented towards services and solutions to enable the transition to a lower-carbon future.
A chemical engineer by training, Conn possesses a deep understanding of the energy sector built up over a lifetime in the industry, with a track record of strategy formulation and delivery, transactions and major projects, commercial innovation, and material turnarounds of large organizations often in the face of very significant challenges.
Over his career Iain has advised governments on energy and climate policy, and from 2017-2020 Iain Co-Chaired the World Economic Forum System Initiative on the Future of Energy. The System Initiative aimed to enable an effective transition to a more sustainable, affordable, secure and inclusive energy system by accelerating development of effective policies, private-sector action and public-private cooperation.
About Blackstone
Blackstone is one of the world’s leading investment firms. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $619 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com . Follow Blackstone on Twitter @Blackstone.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210221005082/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
